“EFFICACY AND RISKS PROFILES OF ‘GLP-1 RECEPTOR AGONISTS’ IN TYPE 2 DIABETES AND OBESITY: A SYSTEMATIC REVIEW OF BENEFITS AND RISKS”, rjnmsr, vol. 3, no. 5, pp. 300–324, Sep. 2025, doi: 10.63075/fmkjkn28.